Long-term effects of adding an SGLT-2 inhibitor to insulin therapy in patients with type 1 diabetes. An observational study and systematic review of real-world evidence.

While glycaemic control remained insufficient and showed a trend worsening in the 5 years before index date, HbA1c rapidly declined after initiation of SGLT2i and remained lower than the baseline value for up to 24 months (Fig. 1 A).

also in 53,322 other papers